 1. Have received or are receiving an investigational medicinal product IMP or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment, or within a period during which the IMP or systemic anticancer treatment has not been cleared from the body e.g. a period of 5 half-lives, whichever is the most appropriate and as judged by the investigator. 